Global Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Region: COVID-19 Impact and Growth Opportunity
- GLO4116845
- 187 Pages
- November 2020
- Healthcare
Highlighted with 85 tables and 84 figures, this 187-page report “Global Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Region: COVID-19 Impact and Growth Opportunity” is based on a holistic research of the entire global preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Region.
Based on Vaccine Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• Recombinant Vector Vaccines
• Other Vaccines
Based on Disease, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Vaccines for Pneumococcal Disease
• Vaccines for Poliovirus
• Vaccines for Hepatitis
• Vaccines for Influenza
• Vaccines for Measles, Mumps, and Rubella (MMR)
• Vaccines for Varicella
• Vaccines for Human Papilloma Virus
• Vaccines for COVID-19
• Vaccines for Other Diseases
Based on Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes
Based on Patient, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
Pediatric Vaccines
• Pneumococcal
• Measles, Mumps, and Rubella (MMR)
• Varicella
• Hepatitis
• Poliovirus
• Haemophilus Influenzae B (HIB)
• Other Diseases
Adult Vaccines
• Influenza
• Cervical Cancer
• Hepatitis
• Zoster
• Other Diseases
Geographically, the following regions together with the listed national/local markets are fully investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
• North America (U.S., Canada, and Mexico)
• South America (Brazil, Columbia, Argentina, Rest of South America)
• MEA (Saudi Arabia, UAE, Egypt)
For each region and key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of all regional markets by country and split of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in global preventive vaccines market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 23
2.1.2 Impact of COVID-19 on the Market 26
2.2 Major Growth Drivers 28
2.3 Market Restraints and Challenges 31
2.4 Emerging Opportunities and Market Trends 34
2.5 Porter’s Fiver Forces Analysis 38
3 Segmentation of Global Market by Vaccine Type 42
3.1 Market Overview by Vaccine Type 42
3.2 Live/Attenuated Vaccines 44
3.3 Inactivated Vaccines 45
3.4 Subunit Vaccines 46
3.5 Toxoid Vaccines 47
3.6 Conjugate Vaccines 48
3.7 Recombinant Vector Vaccines 49
3.8 Other Vaccines 50
4 Segmentation of Global Market by Disease 51
4.1 Market Overview by Disease 51
4.2 Vaccines for Pneumococcal Disease 53
4.3 Vaccines for Poliovirus 54
4.4 Vaccines for Hepatitis 55
4.5 Vaccines for Influenza 56
4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 57
4.7 Vaccines for Varicella 58
4.8 Vaccines for Human Papilloma Virus 59
4.9 Vaccines for COVID-19 60
4.10 Vaccines for Other Diseases 61
5 Segmentation of Global Market by Administration 62
5.1 Market Overview by Administration 62
5.2 Intramuscular Route 64
5.3 Subcutaneous Route 65
5.4 Oral Route 66
5.5 Intravenous Injection 67
5.6 Other Administration Routes 68
6 Segmentation of Global Market by Patient 69
6.1 Market Overview by Patient 69
6.2 Pediatric Vaccines 71
6.3 Adult Vaccines 73
7 Segmentation of Global Market by Region 75
7.1 Geographic Market Overview 2019-2026 75
7.2 North America Market 2019-2026 by Country 79
7.2.1 Overview of North America Market 79
7.2.2 U.S. 82
7.2.3 Canada 87
7.2.4 Mexico 90
7.3 European Market 2019-2026 by Country 93
7.3.1 Overview of European Market 93
7.3.2 UK 96
7.3.3 France 99
7.3.4 Germany 102
7.3.5 Spain 105
7.3.6 Italy 108
7.3.7 Russia 111
7.3.8 Rest of European Market 114
7.4 Asia-Pacific Market 2019-2026 by Country 116
7.4.1 Overview of Asia-Pacific Market 116
7.4.2 China 119
7.4.3 Japan 122
7.4.4 India 126
7.4.5 Australia 129
7.4.6 South Korea 132
7.4.7 Rest of APAC Region 135
7.5 South America Market 2019-2026 by Country 137
7.5.1 Argentina 140
7.5.2 Brazil 143
7.5.3 Columbia 146
7.5.4 Rest of South America Market 149
7.6 MEA Market 2019-2026 by Country 150
7.6.1 UAE 153
7.6.2 Saudi Arabia 156
7.6.3 Egypt 159
7.6.4 Other National Markets 162
8 Competitive Landscape 163
8.1 Overview of Key Vendors 163
8.2 New Product Launch, Partnership, Investment, and M&A 166
8.3 Company Profiles 167
AstraZeneca plc 167
Bavarian Nordic A/S 169
China National Biotec Group Company Ltd. 170
CSL Ltd. 171
Daiichi Sankyo Co. Ltd 172
Emergent BioSolutions Inc. 173
GlaxoSmithKline PLC 174
Johnson & Johnson 175
Merck & Co. 176
Novavax, Inc. 177
Pfizer Inc. 178
Sanofi SA 179
Takeda Pharmaceutical Co. Ltd 180
9 Investing in Global Market: Risk Assessment and Management 181
9.1 Risk Evaluation of Global Market 181
9.2 Critical Success Factors (CSFs) 184
Related Reports and Products 187
Table 2. Growth Rate of World Real GDP, 2017-2021 24
Table 3. Main Product Trends and Market Opportunities in Global Preventive Vaccines Market 34
Table 4. Global Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 42
Table 5. Global Preventive Vaccines Market by Disease, 2016-2026, $ mn 51
Table 6. Global Preventive Vaccines Market by Administration, 2016-2026, $ mn 62
Table 7. Global Preventive Vaccines Market by Patient, 2016-2026, $ mn 69
Table 8. Global Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn 72
Table 9. Global Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn 74
Table 10. Global Preventive Vaccines Market by Region, 2016-2026, $ mn 76
Table 11. Leading National Preventive Vaccines Market, 2019 and 2026, $ mn 78
Table 12. North America Preventive Vaccines Market by Country, 2016-2026, $ mn 81
Table 13. U.S. Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 84
Table 14. U.S. Preventive Vaccines Market by Disease, 2016-2026, $ mn 84
Table 15. U.S. Preventive Vaccines Market by Administration, 2016-2026, $ mn 85
Table 16. Canada Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 88
Table 17. Canada Preventive Vaccines Market by Disease, 2016-2026, $ mn 88
Table 18. Canada Preventive Vaccines Market by Administration, 2016-2026, $ mn 89
Table 19. Mexico Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 91
Table 20. Mexico Preventive Vaccines Market by Disease, 2016-2026, $ mn 91
Table 21. Mexico Preventive Vaccines Market by Administration, 2016-2026, $ mn 92
Table 22. Europe Preventive Vaccines Market by Country, 2016-2026, $ mn 95
Table 23. UK Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 97
Table 24. UK Preventive Vaccines Market by Disease, 2016-2026, $ mn 97
Table 25. UK Preventive Vaccines Market by Administration, 2016-2026, $ mn 98
Table 26. France Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 100
Table 27. France Preventive Vaccines Market by Disease, 2016-2026, $ mn 100
Table 28. France Preventive Vaccines Market by Administration, 2016-2026, $ mn 101
Table 29. Germany Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 103
Table 30. Germany Preventive Vaccines Market by Disease, 2016-2026, $ mn 103
Table 31. Germany Preventive Vaccines Market by Administration, 2016-2026, $ mn 104
Table 32. Spain Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 106
Table 33. Spain Preventive Vaccines Market by Disease, 2016-2026, $ mn 106
Table 34. Spain Preventive Vaccines Market by Administration, 2016-2026, $ mn 107
Table 35. Italy Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 109
Table 36. Italy Preventive Vaccines Market by Disease, 2016-2026, $ mn 109
Table 37. Italy Preventive Vaccines Market by Administration, 2016-2026, $ mn 110
Table 38. Russia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 112
Table 39. Germany Preventive Vaccines Market by Disease, 2016-2026, $ mn 112
Table 40. Germany Preventive Vaccines Market by Administration, 2016-2026, $ mn 113
Table 41. Preventive Vaccines Market in Rest of Europe by Country, 2016-2026, $ mn 115
Table 42. APAC Preventive Vaccines Market by Country, 2016-2026, $ mn 118
Table 43. China Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 120
Table 44. China Preventive Vaccines Market by Disease, 2016-2026, $ mn 120
Table 45. China Preventive Vaccines Market by Administration, 2016-2026, $ mn 121
Table 46. Japan Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 124
Table 47. Japan Preventive Vaccines Market by Disease, 2016-2026, $ mn 124
Table 48. Japan Preventive Vaccines Market by Administration, 2016-2026, $ mn 125
Table 49. India Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 127
Table 50. India Preventive Vaccines Market by Disease, 2016-2026, $ mn 127
Table 51. India Preventive Vaccines Market by C Administration, 2016-2026, $ mn 128
Table 52. Australia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 130
Table 53. Australia Preventive Vaccines Market by Disease, 2016-2026, $ mn 130
Table 54. Australia Preventive Vaccines Market by Administration, 2016-2026, $ mn 131
Table 55. South Korea Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 133
Table 56. South Korea Preventive Vaccines Market by Disease, 2016-2026, $ mn 133
Table 57. South Korea Preventive Vaccines Market by Administration, 2016-2026, $ mn 134
Table 58. Preventive Vaccines Market in Rest of APAC by Country, 2016-2026, $ mn 136
Table 59. South America Preventive Vaccines Market by Country, 2016-2026, $ mn 139
Table 60. Argentina Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 141
Table 61. Argentina Preventive Vaccines Market by Disease, 2016-2026, $ mn 141
Table 62. Argentina Preventive Vaccines Market by Administration, 2016-2026, $ mn 142
Table 63. Brazil Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 144
Table 64. Brazil Preventive Vaccines Market by Disease, 2016-2026, $ mn 144
Table 65. Brazil Preventive Vaccines Market by Administration, 2016-2026, $ mn 145
Table 66. Columbia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 147
Table 67. Mexico Preventive Vaccines Market by Disease, 2016-2026, $ mn 147
Table 68. Mexico Preventive Vaccines Market by Administration, 2016-2026, $ mn 148
Table 69. MEA Preventive Vaccines Market by Country, 2016-2026, $ mn 152
Table 70. UAE Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 154
Table 71. UAE Preventive Vaccines Market by Disease, 2016-2026, $ mn 154
Table 72. UAE Preventive Vaccines Market by Administration, 2016-2026, $ mn 155
Table 73. Saudi Arabia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 157
Table 74. Saudi Arabia Preventive Vaccines Market by Disease, 2016-2026, $ mn 157
Table 75. Saudi Arabia Preventive Vaccines Market by Administration, 2016-2026, $ mn 158
Table 76. Egypt Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 160
Table 77. Egypt Preventive Vaccines Market by Disease, 2016-2026, $ mn 160
Table 78. Egypt Preventive Vaccines Market by Administration, 2016-2026, $ mn 161
Table 79. AstraZeneca plc: Company Snapshot 167
Table 80. AstraZeneca plc: Business Segmentation 167
Table 81. AstraZeneca plc: Product Portfolio 168
Table 82. AstraZeneca plc: Revenue, 2016-2018, $ mn 168
Table 83. AstraZeneca plc: Recent Developments 168
Table 84. Risk Evaluation for Investing in Global Market, 2019-2026 182
Table 85. Critical Success Factors and Key Takeaways 185
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
